This National Cancer Institute (NCI) R01 grant is being offered to support collaborative research projects focused on addressing adverse sequelae of cancer therapies. This grant is for identifying the mechanisms of therapy-induced adverse effects, clinically characterizing them, and translating this understanding into therapeutic approaches to prevent or minimize long-term sequelae. Projects should emphasize basic, translational, and clinical research, particularly mechanistic studies with translational endpoints and longitudinal clinical phenotyping. The purpose is to identify and validate clinical endpoints such as biomarkers or patient-reported outcomes for future clinical trials evaluating intervention efficacy.
Opportunity ID: 357015
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-25-145 |
| Funding Opportunity Title: | Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.393 — Cancer Cause and Prevention Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Nov 06, 2024 |
| Last Updated Date: | Nov 06, 2024 |
| Original Closing Date for Applications: | Jan 07, 2028 |
| Current Closing Date for Applications: | Jan 07, 2028 |
| Archive Date: | Feb 12, 2028 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Native American tribal governments (Federally recognized) Independent school districts Private institutions of higher education Public housing authorities/Indian housing authorities For profit organizations other than small businesses State governments Public and State controlled institutions of higher education Special district governments Native American tribal organizations (other than Federally recognized tribal governments) County governments Others (see text field entitled “Additional Information on Eligibility” for clarification) City or township governments Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-25-145.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 357015 Full Announcement-PAR-25-145 -> PAR-25-145-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-I | Use for due dates on or after January 25, 2025 | PKG00288553 | Jan 05, 2025 | Jan 07, 2028 | View |
Package 1
Mandatory forms
357015 RR_SF424_5_0-5.0.pdf
357015 PHS398_CoverPageSupplement_5_0-5.0.pdf
357015 RR_OtherProjectInfo_1_4-1.4.pdf
357015 PerformanceSite_4_0-4.0.pdf
357015 RR_KeyPersonExpanded_4_0-4.0.pdf
357015 PHS398_ResearchPlan_5_0-5.0.pdf
357015 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
357015 RR_Budget_3_0-3.0.pdf
357015 RR_SubawardBudget30_3_0-3.0.pdf
357015 PHS398_ModularBudget_1_2-1.2.pdf
357015 PHS_AssignmentRequestForm_4_0-4.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
